Literature DB >> 21785361

A novel exonic rearrangement affecting MLH1 and the contiguous LRRFIP2 is a founder mutation in Portuguese Lynch syndrome families.

Manuela Pinheiro1, Carla Pinto, Ana Peixoto, Isabel Veiga, Bárbara Mesquita, Rui Henrique, Manuela Baptista, Maria Fragoso, Olga Sousa, Helena Pereira, Carla Marinho, Luis Moreira Dias, Manuel R Teixeira.   

Abstract

PURPOSE: Although Lynch syndrome is characterized by marked genetic heterogeneity, some specific mutations are observed at high frequency in well-defined populations or ethnic groups due to founder effects.
METHODS: Genomic breakpoint identification, haplotype analysis, and mutation age determination were performed in 14 unrelated patients and 95 family members presenting the same MLH1 exonic rearrangement, among a series of 84 Lynch syndrome families with germline mutations in MLH1, MSH2, or MSH6.
RESULTS: All 14 probands harbored an identical deletion, comprising exons 17-19 of the MLH1 gene and exons 26-29 of the LRRFIP2 gene, corresponding to the MLH1 mutation c.1896 + 280_oLRRFIP2:c.1750-678del. This mutation represents 17% of all deleterious mismatch repair mutations in our series. Haplotype analysis showed a conserved region of approximately 1 Mb, and the mutation age was estimated to be 283 ± 78 years. All 14 families are originated from the Porto district countryside.
CONCLUSION: We have identified a novel MLH1 exonic rearrangement that is a common founder mutation in Lynch syndrome families, indicating that screening for this rearrangement as a first step may be cost-effective during genetic testing of Lynch syndrome suspects of Portuguese ancestry, especially those originating from the Porto district.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21785361     DOI: 10.1097/GIM.0b013e31821dd525

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  8 in total

1.  The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.

Authors:  Sofia Maia; Marta Cardoso; Paula Paulo; Manuela Pinheiro; Pedro Pinto; Catarina Santos; Carla Pinto; Ana Peixoto; Rui Henrique; Manuel R Teixeira
Journal:  Fam Cancer       Date:  2016-01       Impact factor: 2.375

2.  Co-occurrence of nonsense mutations in MSH6 and MSH2 in Lynch syndrome families evidencing that not all truncating mutations are equal.

Authors:  Carla Pinto; Manuela Pinheiro; Ana Peixoto; Catarina Santos; Isabel Veiga; Patrícia Rocha; Pedro Pinto; Paula Lopes; Manuela Baptista; Rui Henrique; Manuel R Teixeira
Journal:  J Hum Genet       Date:  2015-10-08       Impact factor: 3.172

3.  A modifier of Huntington's disease onset at the MLH1 locus.

Authors:  Jong-Min Lee; Michael J Chao; Denise Harold; Kawther Abu Elneel; Tammy Gillis; Peter Holmans; Lesley Jones; Michael Orth; Richard H Myers; Seung Kwak; Vanessa C Wheeler; Marcy E MacDonald; James F Gusella
Journal:  Hum Mol Genet       Date:  2017-10-01       Impact factor: 6.150

4.  The mutational spectrum of Lynch syndrome in cyprus.

Authors:  Maria A Loizidou; Ioanna Neophytou; Demetris Papamichael; Panteleimon Kountourakis; Vassilios Vassiliou; Yiola Marcou; Eleni Kakouri; Georgios Ioannidis; Chrystalla Philippou; Elena Spanou; George A Tanteles; Violetta Anastasiadou; Andreas Hadjisavvas; Kyriacos Kyriacou
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

5.  A survey of the clinicopathological and molecular characteristics of patients with suspected Lynch syndrome in Latin America.

Authors:  Benedito Mauro Rossi; Edenir Inêz Palmero; Francisco López-Kostner; Carlos Sarroca; Carlos Alberto Vaccaro; Florencia Spirandelli; Patricia Ashton-Prolla; Yenni Rodriguez; Henrique de Campos Reis Galvão; Rui Manuel Reis; André Escremim de Paula; Luis Gustavo Capochin Romagnolo; Karin Alvarez; Adriana Della Valle; Florencia Neffa; Pablo German Kalfayan; Enrique Spirandelli; Sergio Chialina; Melva Gutiérrez Angulo; Maria Del Carmen Castro-Mujica; Julio Sanchez de Monte; Richard Quispe; Sabrina Daniela da Silva; Norma Teresa Rossi; Claudia Barletta-Carrillo; Susana Revollo; Ximena Taborga; L Lena Morillas; Hélène Tubeuf; Erika Maria Monteiro-Santos; Tamara Alejandra Piñero; Constantino Dominguez-Barrera; Patrik Wernhoff; Alexandra Martins; Eivind Hovig; Pål Møller; Mev Dominguez-Valentin
Journal:  BMC Cancer       Date:  2017-09-05       Impact factor: 4.430

6.  Germline MLH1, MSH2 and MSH6 variants in Brazilian patients with colorectal cancer and clinical features suggestive of Lynch Syndrome.

Authors:  Nayê Balzan Schneider; Tatiane Pastor; André Escremim de Paula; Maria Isabel Achatz; Ândrea Ribeiro Dos Santos; Fernanda Sales Luiz Vianna; Clévia Rosset; Manuela Pinheiro; Patricia Ashton-Prolla; Miguel Ângelo Martins Moreira; Edenir Inêz Palmero
Journal:  Cancer Med       Date:  2018-03-25       Impact factor: 4.452

7.  Haplotype analysis suggest that the MLH1 c.2059C > T mutation is a Swedish founder mutation.

Authors:  Jenny von Salomé; Tao Liu; Markku Keihäs; Moni Morak; Elke Holinski-Feder; Ian R Berry; Jukka S Moilanen; Stéphanie Baert-Desurmont; Annika Lindblom; Kristina Lagerstedt-Robinson
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

8.  Target gene mutational pattern in Lynch syndrome colorectal carcinomas according to tumour location and germline mutation.

Authors:  Manuela Pinheiro; Carla Pinto; Ana Peixoto; Isabel Veiga; Paula Lopes; Rui Henrique; Helena Baldaia; Fátima Carneiro; Raquel Seruca; Ian Tomlinson; Michal Kovac; Karl Heinimann; Manuel R Teixeira
Journal:  Br J Cancer       Date:  2015-08-06       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.